Samuel B.

Background

About Samuel B.

Conifer Point Pharmaceuticals provides guidance to pharmaceutical and biotech companies during early stage drug discovery ventures.In my current role, I have:• Delivered analysis of small molecule analogs and natural products to develop hit discovery and hit-to-lead research pipelines through Schrodinger Maestro and Boltzmann Maps software suites and other computation-based methods• Applied docking, pharmacophore modeling, QSAR modeling and shape screening of large natural product and small molecule compound libraries• Developed synthetic strategies for use by CROs and internally within a diverse cross-functional team• Analyzed in vitro data to evaluate ADME properties and potency of compounds to make recommendations to prioritize and progress lead optimization• Delivered analysis of patents and prior art pursuant to the development of novel therapeutic agents with Reaxys, InnovationQ, and USPTO resources• Reviewed FDA regulations and provided guidance for clients filing Investigatory New Drug (IND) applications to provide structural biology profiles of drug targetsThrough my career, I have:• Focused on the optimization of pre-clinical novel drug targets, drug discovery and innovation in the rapidly growing biomedical space• Designed and synthesized novel small molecules for the treatment of infectious disease• Designed and synthesized macromolecules in the development of drug delivery vehicles and to elucidate mechanism of action and binding modes for complex cancer progression pathways• Engaged in iterative SAR, ADME and in vivo studies en route to clinical drug candidates• Employed methods in medicinal and organic chemistry to synthesize hundreds of compounds for the development and optimization of disease treatment• Employed analytical methods including HLPC, SEC-HPLC, MS, NMR, FTIR, and several more, in the evaluation of synthetic targets